North American Scientific Announces Agreement With ONCURA for Distribution of Pd-103 Brachytherapy Seeds

Business Wire, July 21, 2005

CHATSWORTH, Calif. -- North American Scientific, Inc. (Nasdaq:NASI) today announced that it has entered into a worldwide non-exclusive agreement to supply its Prospera(R) palladium-103 prostate brachytherapy source to ONCURA(TM), a global leader in the minimally invasive management of prostate cancer. The agreement, which begins on September 9th, 2005, is intended to run for a five year period. North American Scientific will continue to sell its Prospera(R) Pd-103 brachytherapy source directly through its own sales force. North American Scientific has sold over one million palladium-103 seeds since its 1999 introduction. Prospera Pd-103 is supported by the peer reviewed, published dosimetry studies recommended by the American Association of Physicists in Medicine (AAPM).

"We believe that our agreement with ONCURA, with its extensive sales and marketing team, could significantly expand the sales of our Prospera palladium source with its proven record of excellence," stated L. Michael Cutrer, President and Chief Executive Officer of North American Scientific. "All of us at North American Scientific look forward to an outstanding relationship with ONCURA over the course of our agreement."

"ONCURA has entered into this arrangement to ensure that we fully satisfy the needs of all prostate brachytherapy customers," said James McGlone, President and CEO of ONCURA. He added, "We've increased our long-term commitment to the brachytherapy community and look forward to the opportunity of providing an enhanced level of service; this agreement will allow us to do so."

About North American Scientific

North American Scientific is a leader in radiation therapy products and services in the fight against cancer. Its innovative products provide physicians with a set of tools for the treatment of various types of cancers. They include radioisotope-based brachytherapy seeds, used primarily in the treatment of prostate cancer, marketed under the trade name Prospera(R); Intensity Modulated Radiation Therapy (IMRT); and Image Guided Radiation Therapy (IGRT). IMRT allows an escalated radiation dose to be delivered to a tumor while limiting exposure and damage to nearby healthy tissue. The Company's principal IMRT products are marketed under the trade names PEACOCK(R) and CORVUS. The Company's IGRT products, BAT(R), BATCAM(TM) and nTRAK(TM) provide fast and accurate targeting and localization of a treatment volume on a daily basis. Over 500 hospitals and research sites worldwide are equipped with the Company's clinically proven PEACOCK, CORVUS (our proprietary treatment planning software), BAT, BATCAM, and ancillary treatment solutions. Please visit www.nasmedical.com for more information.

About ONCURA

ONCURA was created through the merger of Amersham plc's (now GE Healthcare) brachytherapy business and Galil Medical Ltd's urology business. Galil is a subsidiary of Elron (ELRN). Headquartered in the United States, ONCURA operates as an independent business, with a major presence in the treatment of prostate cancer. ONCURA's International business is operated from its UK subsidiary. Please visit www.oncura.com for more information.

Statements included in this release that are not historical facts may be considered forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company including, but not limited to, uncertainties relating to drug discovery and clinical development processes, the impact of competitive products and technological changes, changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements, the ability of the Company to successfully directly market and sell its brachytherapy products, uncertainties relating to patent protection and regulatory approval, the stable supply of appropriate isotopes, the impact of competitive products and pricing, research and development estimates, market opportunities, risks associated with strategic opportunities or acquisitions the Company may pursue and the risk factors included in the Company's filings with the Securities and Exchange Commission. Any forward-looking statements contained in this news release speak only as of the date of this release, and the Company undertakes no obligation to revise or update any forward-looking statements, whether as a result of new information, future results or otherwise.